Redeye provides its initial comments on the report ahead of a more detailed update discussing the ca...
Redeye comments on Impact Coatings Q4 report which only included minor deviations from our forecasts...
Redeye is encouraged to see another quarter of solid improvement.
EAB reported H2 comparable operating income of EUR 11.
Rovio’s Q4 report offered a 7% beat on revenue and 35% beat on adjusted EBIT relative to Infront con...
Redeye recognizes Bambuser's high sequential growth rates in Q4, which align with expectations.
Redeye comments on QleanAir’s reported Q4’21 figures, where organic sales growth exceeded our expect...
Redeye comments on the announced rights issue in Alzecure.
Redeye comment on Remedy’s full-year report. Remedy posted an EBIT result in line with our estimated...
Q4 quite in line with expectations Etteplan reported Q4 results quite in line with expectations.
Tough quarter behind The company’s net sales decreased by 4% y/y to EUR 168.
Sparekassen Sjælland-Fyn reported profit before loan losses of DKK 105m for Q4 2021, which was a who...
Redeye is encouraged to learn that the ongoing SAN711 phase I study (n=80), now in the MAD (”multipl...
Den 10 februari 2022 publicerade Aptahem sin delårsrapport för fjärde kvartalet 2021.
Redeye endorses aXichem signing a business collaboration agreement with GCV Life to commercialize aX...
Etteplan's net sales in Q4 amounted to EUR 85.3m (EUR 82.
Sparekassen Sjælland-Fyn reported Q4 PBLL of DKK 105m, DKK 18m (21%) above our estimate.
Starkt resultat ITAB rapporterade en EBIT på 224 mkr, vilket var i linje med vår prognos (216 mkr).
Ascelia continues to advance the pivotal Mangoral (Orviglance) study, which is also supported by rec...
Redeye sees a solid Q4 from Bredband2, with sales and EBIT coming in as we expected.
